Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number 10511537 Filing Date 2004-10-15 First Named Inventor Tiden Art Unit 1624 Examiner Name Mark L. Berch Attorney Docket Number 100647-1P US

					U.S.I	PATENTS			Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	ate Name of Patentee or Applicant		Releva		Lines where ges or Relev	
	1	5489598		1996-02	2-06	Connor et al.					
If you wisl	h to a	⊥ dd additional U.S. Patei	nt citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBI	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Pate of cited Docu	entee or Applicant ment	Releva		Lines where ges or Relev	
	1	20050070558		2005-03	005-03-31 Vidal Juan et al.						
	2	20070093483		2007-04-26 Svensson et al.							
If you wisl	h to a	⊥ dd additional U.S. Publi	shed Ap	plication	citatio	ı n information p	olease click the Add	d button	Add		
				FOREIC	3N PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patented Applicant of cited Document	e or 	where Rel	or Relevant	T5
	1	0359505	EP			1990-03-21	Smithkline Beechar Corporation	m			
	2	0452926	EP			1996-03-13	Merrell Dow Pharmaceuticals In	C.			
		/Mark Barch/ (05/	0.7/0000								oxdot

/Mark Berch/ (05/07/2008)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10511537		
Filing Date		2004-10-15		
First Named Inventor Tiden				
Art Unit		1624		
Examiner Name Mark		L. Berch		
Attorney Docket Number		100647-1P US		

3	02160235	JP	1990-06-20	Konica Corp	
4	8906125	WO	1989-07-13	Smithkline Beechman Corporation	
5	9914204	WO	1999-03-25	G.D. Searle & Co.	
6	9940091	WO	1999-08-12	Amgen Inc.	
7	0059449	WO	2000-10-12	Euro-Celtique S.A.	
8	02006272	WO	2002-01-24	Sanofi-Synthelabo	
9	02066447	WO	2002-08-29	Ono Pharmaceutical Co., Ltd	
10	03000694	WO	2003-01-03	Almirall Prodesfarma S. A.	
11	03082873	WO	2003-10-09	Almirall Prodesfarma S. A.	
12	2004096781	WO	2004-11-11	AstraZeneca AB	
13	2005042534	WO	2005-05-12	CV Therapeutics Inc.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10511537
Filing Date		2004-10-15
First Named Inventor Tiden		
Art Unit		1624
Examiner Name Mark		L. Berch
Attorney Docket Number		100647-1P US

	14	2006046910	WO		2006-05-04	AstraZeneca AB		
	15	2006062465	WO		2006-06-15	AstraZeneca AB		
	16	2007142576	WO		2007-12-13	AstraZeneca AB		
If you wish	h to ac	d additional Foreign Pa	atent Document	citation	information pl	ease click the Add butto	n Add	
			NON-PATEN	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T 5
	1	IMAI et al., "Studies on Nucleic Acid Antagonists. VII. Synthesis and Characterization of 1,4,6-Triazaindenes (5H-Pyrrolo(3,2-d)pyrimidines)" Chem. Pharm. Bull., 1964, Vol. 12, No. 9, pgs. 1030-1042						
	2	KOLASA et al., "Reactions of Alpha-Hydroxy Carbonyl Compounds With Azodicarboxylates and Triphenylphosphine: Synthesis of Alpha-N-Hydroxy Amino Acid Derivatives," Journal of Organic Chemistry, 1987, Vol. 52, pgs 4978-4984						
	3	RAO et al., "Synthesis of 5,7-Disubstituted-4-Beta-D-ribofuranosylpyrazolo[4,3-d]-pyrimidines and 2,4-Disubstituted-1-Beta-D-ribofuranosylpyrrolo[3,2-d]-pyrimidines as Congeners of Uridine and Cytidine," J. Heterocyclic Chemistry, 1992, Vol. 29, pgs 343-354						
	4	STN Intnl, Registry No. 2487-40-3 (Entered into STN: 16 Nov 1984)						
	5	English abstract for JP 02160235 (1990)						
	6	English abstract for WO	2002006272	(2)	002)			

/Mark Berch/ (05/07/2008)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10511537
Filing Date		2004-10-15
First Named Inventor Tiden		
Art Unit		1624
Examiner Name Mark		L. Berch
Attorney Docket Number		100647-1P US

	7	Co-Pending U.S. Application No. 11/756967, Attorney Docket No. 102288-2 US, filed on June 1, 2007						
	8	Co-Pending U.S. Application No. 11/577833, Attorney Docket No. 101584-1P US, filed on April 24, 2007						
	9	Co-Pending U.S. Application No. 11/720913, Attorney Docket No. 101621-1P US, filed on June 5, 2007						
If you wisl	h to ac	dd additional non-patent literature document citation information	please click the Add b	outton Add				
		EXAMINER SIGNATURE						
Examiner	Signa	ature /Mark Berch/ (05/07/2008)	Date Considered					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. I Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.								